Prognostic and predictive value of p53 and p21 in breast cancer
暂无分享,去创建一个
[1] C K Osborne,et al. Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer. An intergroup study. , 1989, The New England journal of medicine.
[2] P. Isaacson,et al. Immunoproliferative small-intestinal disease. An immunohistochemical study. , 1989, The American journal of surgical pathology.
[3] G. Lozano,et al. Transcriptional activation by wild-type but not transforming mutants of the p53 anti-oncogene. , 1990, Science.
[4] E. Appella,et al. Negative growth regulation in a glioblastoma tumor cell line that conditionally expresses human wild-type p53. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[5] N. Davidson,et al. Programmed cell death during regression of the MCF-7 human breast cancer following estrogen ablation. , 1991, Cancer research.
[6] A. Kimchi,et al. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6 , 1991, Nature.
[7] B. Angus,et al. p53 expression in human breast cancer related to survival and prognostic factors: An immunohistochemical study , 1991, The Journal of pathology.
[8] S. Hirohashi,et al. Nuclear p53 Immunoreaction Associated with Poor Prognosis of Breast Cancer , 1991, Japanese journal of cancer research : Gann.
[9] J. Marks,et al. Maintenance of p53 alterations throughout breast cancer progression. , 1991, Cancer research.
[10] K. Kinzler,et al. Identification of p53 as a sequence-specific DNA-binding protein , 1991, Science.
[11] B. Angus,et al. Retinoblastoma and p53 gene expression related to relapse and survival in human breast cancer: An immunohistochemical study , 1992, The Journal of pathology.
[12] W. McGuire,et al. Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] P. Friedman,et al. Wild-type p53 activates transcription in vitro , 1992, Nature.
[14] S. Friend,et al. A functional screen for germ line p53 mutations based on transcriptional activation. , 1992, Cancer research.
[15] E. Kawasaki,et al. Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. , 1992, Journal of the National Cancer Institute.
[16] G. Gitsch,et al. Immunohistochemical detection of mutant p53-suppressor gene product in patients with breast cancer: influence on metastasis-free survival. , 1992, Anticancer research.
[17] I. Ellis,et al. p53 protein expression in human breast carcinoma: relationship to expression of epidermal growth factor receptor, c-erbB-2 protein overexpression, and oestrogen receptor. , 1992, British Journal of Cancer.
[18] T. Visakorpi,et al. Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. , 1992, Journal of the National Cancer Institute.
[19] E. Appella,et al. Growth arrest induced by wild-type p53 protein blocks cells prior to or near the restriction point in late G1 phase. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[20] P. Shaw,et al. Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[21] Thea D. Tlsty,et al. Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53 , 1992, Cell.
[22] A. Levine,et al. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation , 1992, Cell.
[23] A. Levine,et al. Wild-type p53 mediates positive regulation of gene expression through a specific DNA sequence element. , 1992, Genes & development.
[24] David Beach,et al. p21 is a universal inhibitor of cyclin kinases , 1993, Nature.
[25] A. Wärri,et al. Apoptosis in toremifene-induced growth inhibition of human breast cancer cells in vivo and in vitro. , 1993, Journal of the National Cancer Institute.
[26] S. Syrjänen,et al. p53 protein expression in breast cancer as related to histopathological characteristics and prognosis , 1993, International journal of cancer.
[27] C. Purdie,et al. Thymocyte apoptosis induced by p53-dependent and independent pathways , 1993, Nature.
[28] U. Veronesi,et al. p53 as an independent prognostic marker in lymph node-negative breast cancer patients. , 1993, Journal of the National Cancer Institute.
[29] A. Levine,et al. The p53-mdm-2 autoregulatory feedback loop. , 1993, Genes & development.
[30] W. McGuire,et al. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. , 1993, Journal of the National Cancer Institute.
[31] J. Pipas,et al. Specific repression of TATA-mediated but not initiator-mediated transcription by wild-type p53 , 1993, Nature.
[32] D. Beach,et al. Proliferating cell nuclear antigen and p21 are components of multiple cell cycle kinase complexes. , 1993, Molecular biology of the cell.
[33] F. Sarkar,et al. Clinicopathologic significance of p53 immunostaining in adenocarcinoma of the breast. , 1993, Archives of pathology & laboratory medicine.
[34] D. Barnes,et al. Immunohistochemical detection of p53 protein in mammary carcinoma: an important new independent indicator of prognosis? , 1993, Human pathology.
[35] E. Winchester,et al. Inhibition of DNA replication factor RPA by p53 , 1993, Nature.
[36] M. Noguchi,et al. Prognostic-significance of p53 and C-erbb-2 expression in operable breast-cancer. , 1993, International journal of oncology.
[37] K. Heimdal,et al. Prognostic significance of TP53 alterations in breast carcinoma. , 1993, British Journal of Cancer.
[38] J. Lotem,et al. Hematopoietic cells from mice deficient in wild-type p53 are more resistant to induction of apoptosis by some agents. , 1993, Blood.
[39] J. Trent,et al. WAF1, a potential mediator of p53 tumor suppression , 1993, Cell.
[40] K. Friedrichs,et al. Overexpression of p53 and prognosis in breast cancer , 1993, Cancer.
[41] J. Eyfjörd,et al. Somatic p53 mutations in human breast carcinomas in an Icelandic population: a prognostic factor. , 1993, Cancer research.
[42] J. Roth,et al. A retroviral wild-type p53 expression vector penetrates human lung cancer spheroids and inhibits growth by inducing apoptosis. , 1993, Cancer research.
[43] D. Housman,et al. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents , 1993, Cell.
[44] J. Benhattar,et al. p53 Gene alterations and p53 protein accumulation in infiltrating ductal breast carcinomas: correlation between immunohistochemical and molecular biology techniques. , 1994, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.
[45] I. Runnebaum,et al. Wild-type p53 suppresses the malignant phenotype in breast cancer cells containing mutant p53 alleles. , 1994, Anticancer research.
[46] W. Dupont,et al. P53 gene mutations and steroid receptor status in breast cancer. Clinicopathologic correlations and prognostic assessment , 1994, Cancer.
[47] M. Noguchi,et al. Immunohistochemical detection of p53 and c-erbB-2 proteins: Prognostic significance in operable breast cancer , 1994, Breast cancer.
[48] D. Housman,et al. p53 status and the efficacy of cancer therapy in vivo. , 1994, Science.
[49] A. Harris,et al. Prognostic value of p53 expression in early-stage breast-carcinoma compared with tumor angiogenesis, epidermal growth-factor receptor, C-erbb-2, cathepsin-d, DNA-ploidy, parameters of cell-kinetics and conventional features. , 1994, International journal of oncology.
[50] G. Striker,et al. p53 protein and vimentin in invasive ductal NOS breast carcinoma--relationship with survival and sites of metastases. , 1994, European journal of cancer.
[51] N. Weidner,et al. Tumor microvessel density, p53 expression, tumor size, and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[52] R. Elledge,et al. p53 protein accumulation detected by five different antibodies: relationship to prognosis and heat shock protein 70 in breast cancer. , 1994, Cancer research.
[53] D. Schaid,et al. p53 gene mutations in breast cancers in midwestern US women: null as well as missense-type mutations are associated with poor prognosis. , 1994, Oncogene.
[54] S. Cha,et al. p53 gene expression in node-positive breast cancer: relationship to DNA ploidy and prognosis. , 1994, Journal of the National Cancer Institute.
[55] D. Birnbaum,et al. Breast cancer response to adjuvant chemotherapy in correlation with erbB2 and p53 expression. , 1994, Anticancer research.
[56] K. Dameron,et al. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. , 1994, Science.
[57] M. Espié,et al. p53 mutations and overexpression in locally advanced breast cancers. , 1994, British Journal of Cancer.
[58] S. Lowe,et al. p53-Dependent apoptosis suppresses tumor growth and progression in vivo , 1994, Cell.
[59] S. Friend,et al. Overcoming complexities in genetic screening for cancer susceptibility. , 1994, Cold Spring Harbor symposia on quantitative biology.
[60] J. Roth,et al. Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. , 1994, Cancer research.
[61] M. Stenmark-Askmalm,et al. Cellular accumulation of p53 protein: an independent prognostic factor in stage II breast cancer. , 1994, European journal of cancer.
[62] D. Berry,et al. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. , 1994, The New England journal of medicine.
[63] J. Marks,et al. Overexpression of p53 and HER‐2/neu Proteins as Prognostic Markers in Early Stage Breast Cancer , 1994, Annals of surgery.
[64] D. Birnbaum,et al. p53 immunohistochemical analysis in breast cancer with four monoclonal antibodies: comparison of staining and PCR-SSCP results. , 1994, British Journal of Cancer.
[65] I. Ellis,et al. Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy. , 1995, British Journal of Cancer.
[66] M. Stenmark-Askmalm,et al. p53 as a prognostic factor in stage I breast cancer. South-East Sweden Breast Cancer Group. , 1995, British Journal of Cancer.
[67] K. Kinzler,et al. p21 is necessary for the p53-mediated G1 arrest in human cancer cells. , 1995, Cancer research.
[68] P. Workman. To pop or not to pop: p53 as a critical modulator of tumour responsiveness to therapy in vivo? , 1995, Human & experimental toxicology.
[69] L. Cox,et al. A direct effect of activated human p53 on nuclear DNA replication. , 1995, The EMBO journal.
[70] J. Eyfjörd,et al. TP53 mutations and abnormal p53 protein staining in breast carcinomas related to prognosis. , 1995, European journal of cancer.
[71] R. Tjian,et al. p53 transcriptional activation mediated by coactivators TAFII40 and TAFII60. , 1995, Science.
[72] R. Gray,et al. Accumulation of p53 protein as a possible predictor of response to adjuvant combination chemotherapy with cyclophosphamide, methotrexate, fluorouracil, and prednisone for breast cancer. , 1995, Journal of the National Cancer Institute.
[73] L. Skoog,et al. p53 expression and the result of adjuvant therapy of breast cancer. , 1995, Acta oncologica.
[74] L. Norton,et al. p53 in node-negative breast carcinoma: an immunohistochemical study of epidemiologic risk factors, histologic features, and prognosis. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[75] G. Hortobagyi,et al. p53 and c-erbB-2 expression and response to preoperative chemotherapy in locally advanced breast carcinoma , 1995 .
[76] V. Kosma,et al. Expression of p53 protein has no independent prognostic value in breast cancer , 1995, The Journal of pathology.
[77] G. Jacobsen,et al. An immunohistochemical study of p53 with correlations to histopathological parameters, c-erbB-2, proliferating cell nuclear antigen, and prognosis. , 1995, Human pathology.
[78] L. Holmberg,et al. p53 Status predicts survival in breast cancer patients treated with or without postoperative radiotherapy: a novel hypothesis based on clinical findings. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[79] Y. Kang,et al. Effects of tamoxifen on growth and apoptosis of estrogen-dependent and -independent human breast cancer cells , 1995, Annals of surgical oncology.
[80] S. Hilsenbeck,et al. p53 mutation and tamoxifen resistance in breast cancer. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.
[81] L. Holmberg,et al. Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy , 1995, Nature Medicine.
[82] M. Fernö,et al. Prognostic significance of p53 overexpression in primary breast cancer; a novel luminometric immunoassay applicable on steroid receptor cytosols. , 1995, British Journal of Cancer.
[83] S. Schnitt,et al. Loss of tumor marker-immunostaining intensity on stored paraffin slides of breast cancer. , 1996, Journal of the National Cancer Institute.
[84] P. Chikhlikar,et al. Node negative breast carcinoma: Hyperprolactinemia and/or overexpression of p53 as an independent predictor of poor prognosis compared to newer and established prognosticators , 1996, Journal of surgical oncology.
[85] A. Harris,et al. p21WAF1 immunohistochemical expression in breast carcinoma: correlations with clinicopathological data, oestrogen receptor status, MIB1 expression, p53 gene and protein alterations and relapse-free survival. , 1996, British Journal of Cancer.
[86] D. Horsfall,et al. Relationship between p53 gene abnormalities and other tumour characteristics in breast‐cancer prognosis , 1996, International journal of cancer.
[87] R. Bast,et al. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. , 1996, Journal of the National Cancer Institute.
[88] W. El-Deiry,et al. Regulation of p21WAF1/CIP1 expression by p53-independent pathways. , 1996, Oncogene.
[89] J. Eyfjörd,et al. TP53 mutation analyses on breast carcinomas: a study of paraffin-embedded archival material. , 1996, British Journal of Cancer.
[90] J. Foekens,et al. Prognostic significance of TP53 accumulation in human primary breast cancer: Comparison between a rapid quantitative immunoassay and SSCP analysis , 1996, International journal of cancer.
[91] David E. Housman,et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours , 1996, Nature.
[92] J. Foekens,et al. TP53 and MYC gene alterations independently predict poor prognosis in breast cancer patients , 1996, Genes, chromosomes & cancer.
[93] R. Elledge. Assessing p53 status in breast cancer prognosis: where should you put the thermometer if you think your p53 is sick? , 1996, Journal of the National Cancer Institute.
[94] T. Aas,et al. Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients , 1996, Nature Medicine.
[95] A. Lazaris,et al. PROGNOSTIC SIGNIFICANCE OF THE CO‐EXPRESSION OF p53 AND c‐erbB‐2 PROTEINS IN BREAST CANCER , 1996, The Journal of pathology.
[96] J. Coindre,et al. Primary chemotherapy in breast invasive carcinoma: predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MiB1, pS2 and GST pi. , 1996, British Journal of Cancer.
[97] N. Bouck. P53 and angiogenesis. , 1996, Biochimica et biophysica acta.
[98] A. Harris,et al. Prognostic value of p21(WAF1) and p53 expression in breast carcinoma: an immunohistochemical study in 261 patients with long-term follow-up. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.
[99] B. Angus,et al. p53 protein as a prognostic indicator in breast carcinoma: a comparison of four antibodies for immunohistochemistry. , 1996, British Journal of Cancer.
[100] L. Holmberg,et al. The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry. , 1996, Journal of the National Cancer Institute.
[101] U. Veronesi,et al. Expression of p53, glutathione S-transferase-pi, and Bcl-2 proteins and benefit from adjuvant radiotherapy in breast cancer. , 1997, Journal of the National Cancer Institute.
[102] A. Yang,et al. Monoallelically Expressed Gene Related to p53 at 1p36, a Region Frequently Deleted in Neuroblastoma and Other Human Cancers , 1997, Cell.
[103] K. Kinzler,et al. 14-3-3σ Is a p53-Regulated Inhibitor of G2/M Progression , 1997 .
[104] André Goffeau,et al. Molecular fish on chips , 1997, Nature.
[105] J. Selkirk,et al. p53-dependent p21 induction following gamma-irradiation without concomitant p53 induction in a human peripheral neuroepithelioma cell line. , 1997, Cancer research.
[106] A. Schäffer,et al. Genetic heterogeneity and clonal evolution underlying development of asynchronous metastasis in human breast cancer. , 1997, Cancer research.
[107] T. Aas,et al. Absence of p21 expression is associated with abnormal p53 in human breast carcinomas. , 1997, British Journal of Cancer.
[108] Raouf Fetni,et al. A p53-independent pathway for induction of p21waf1cip1 and concomitant G1 arrest in UV-irradiated human skin fibroblasts. , 1997, Cancer research.
[109] B. Iacopetta,et al. Detection of p53 gene mutation by rapid PCR‐SSCP and its association with poor survival in breast cancer , 1997, International journal of cancer.
[110] Z. Shao,et al. p21/waf1/cip1 and mdm‐2 expression in breast carcinoma patients as related to prognosis , 1997, International journal of cancer.
[111] J. Foekens,et al. p53 protein accumulation predicts poor response to tamoxifen therapy of patients with recurrent breast cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[112] R. Gray,et al. Survival advantage of adjuvant chemotherapy in high-risk node-negative breast cancer: ten-year analysis--an intergroup study. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[113] M. J. van de Vijver,et al. p53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[114] U. Göhring,et al. P53 protein in 204 patients with primary breast carcinoma — immunohistochemical detection and clinical value as a prognostic factor , 2004, Archives of Gynecology and Obstetrics.
[115] R. Elledge,et al. WAF1/CIP1 protein expression in human breast tumors , 1997, Breast Cancer Research and Treatment.
[116] W. McGuire,et al. Prognostic significance of p53 gene alterations in node-negative breast cancer , 2004, Breast Cancer Research and Treatment.
[117] J. Coindre,et al. Prognostic value of p53 in breast invasive ductal carcinoma: an immunohistochemical study on 942 cases , 2004, Breast Cancer Research and Treatment.
[118] M. Espié,et al. Is p53 a protein that predicts the response to chemotherapy in node negative breast cancer? , 2004, Breast Cancer Research and Treatment.
[119] G. Viale,et al. Abnormalp53 immunoreactivity and prognosis in node-negative breast carcinomas with long-term follow-up , 2005, Virchows Archiv A.
[120] A. Reiner,et al. Coexpression of HER-2/neu and p53 is associated with a shorter disease-free survival in node-positive breast cancer patients , 2005, Journal of Cancer Research and Clinical Oncology.
[121] N. Sneige,et al. Abnormal expression of MDM-2 in breast carcinomas , 2005, Breast Cancer Research and Treatment.